Copyright
©The Author(s) 2023.
World J Gastrointest Oncol. Mar 15, 2023; 15(3): 405-424
Published online Mar 15, 2023. doi: 10.4251/wjgo.v15.i3.405
Published online Mar 15, 2023. doi: 10.4251/wjgo.v15.i3.405
Table 5 Ongoing clinical trials that combine locoregional therapies with immune checkpoint inhibitors
Main intervention methods | Comparison arms | Trial identifier | Status | Estimated or actual enrollment | Patient group | Phase |
Pembrolizumab + RAF/MWA/brachytherapy/TACE | vs Pembrolizumab + RAF/MWA/brachytherapy/TACE | NCT03753659 | Active, not recruiting | 30 | Early-stage HCC | II |
Nivolumab + TACE | No | NCT03572582 | Active, not recruiting | 49 | Intermediate-stage HCC | II |
Pembrolizumab + TACE | No | NCT03397654 | Active, not recruiting | 26 | HCC | I/II |
Durvalumab + tremelimumab + TACE/RAF/cryoablation | vs Durvalumab + tremelimumab | NCT02821754 | Active, not recruiting | 54 | Advanced HCC | II |
Durvalumab + tremelimumab + TACE | No | NCT03638141 | Recruiting | 30 | Intermediate-stage HCC | II |
Durvalumab + tremelimumab + bevacizumab + TACE | No | NCT03937830 | Recruiting | 22 | Advanced HCC | II |
Durvalumab + bevacizumab + TACE | vs Durvalumab + TACE vs TACE | NCT03778957 | Active, not recruiting | 724 | Intermediate-stage HCC | III |
Apatinib + camrelizumab + HAIC | No | NCT04191889 | Recruiting | 84 | Advanced HCC | II |
Pembrolizumab + SBRT | No | NCT03316872 | Recruiting | 30 | Advanced HCC | II |
Durvalumab + tremelimumab + SBRT | No | NCT03482102 | Recruiting | 70 | Advanced HCC | II |
Nivolumab + curative resection/RAF | vs Curative resection/RAF | NCT03383458 | Active, not recruiting | 545 | Resected HCC | III |
Durvalumab + bevacizumab + curative resection/RAF | vs Durvalumab + curative resection/RAF vs Curative resection/RAF | NCT03847428 | Active, not recruiting | 877 | Resected HCC | III |
Ipilimumab + nivolumab + TACE | vs Nivolumab + TACE + placebo vs TACE + placebo + placebo | NCT04340193 | Active, not recruiting | 26 | Intermediate-stage HCC | III |
Lenvatinib + pembrolizumab + TACE | vs Placebo + placebo + TACE | NCT04246177 | Active, not recruiting | 950 | Incurable/non-metastatic HCC | III |
Nivolumab + DEB TACE | vs DEB TACE | NCT04268888 | Recruiting | 522 | Intermediate-stage HCC | II/III |
- Citation: Luo YZ, Zhu H. Immunotherapy for advanced or recurrent hepatocellular carcinoma. World J Gastrointest Oncol 2023; 15(3): 405-424
- URL: https://www.wjgnet.com/1948-5204/full/v15/i3/405.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v15.i3.405